Drug Trial Radar · NCT00811421
Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy
Last checked: Nov 19, 2026Latest source record: Mar 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,820
Actual
Start
Sep 2009
Primary completion
Dec 2012
Study completion Dec 2013
Sponsor
- Lead sponsor
- Hospital Clinic of BarcelonaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Barcelona Centre for International Health Research; Institute of Tropical Medicine, University of Tuebingen; Institut de Recherche pour le Developpement; Université d'Abomey-Calavi; Albert Schweitzer Hospital; Kenya Medical Research Institute; Ifakara Health Institute; Centro de Investigacao em Saude de Manhica; Vienna School of Clinical Research (VSCR), Austria.; Centers for Disease Control and Prevention; Malaria in Pregnancy Consortium
- First posted
- Dec 19, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- Female only
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study aims at comparing the safety, tolerability and efficacy of Mefloquine (MQ) to Sulfadoxine-Pyrimethamine (SP) as Interment Preventive Treatment in pregnancy (IPTp) for the prevention of malaria effects on the mother and her infant.
Conditions
- Pregnancy
- Malaria
- HIV Infections
Interventions
Sulphadoxine-pyrimethamineDrug
SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
Mefloquine (full dose)Drug
MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
Mefloquine (split dose)Drug
MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
placeboDrug
MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
mefloquineDrug
MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
Primary outcomes
What the sponsor says the trial is designed to measure.
- Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.Time frame: day 0, birth
- Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.Time frame: day 0, delivery
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Faculté des Sciences de la Santé (FSS), Université d'Abomey Calavi
Allada, Benin
Medical Rsearch Unit (MRU), Albert Schweitzer Hospital
Lambaréné, Gabon
Kenya Medical Research Institute (KEMRI)/ CDC
Kisumu, Kenya
Centro de Investigaçao em Saúde da Manhiça (CISM)
Manhiça, Maputo Province, Mozambique
Ifakara Health Institute (IHI)
Dodoma, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.